Taiho Oncology, Inc.
Muriel Granier is currently a Senior Director in Clinical Research Scientist Clinical Development at Taiho Oncology, Inc. Prior to this role, Muriel held various positions at companies such as Incyte, AAREC Filia Research-AFR, CHUV, Beaujon Hospital-APHP, Nuvisan, Sanofi, AAIOncology, Cvitkovic & Associés Consultants, and Gustave Roussy. Muriel's educational background includes a Diplôme Inter-Universitaire de Formation des Attachés de Recherche Clinique from Pierre and Marie Curie University, a Diplôme d'Etat Infirmière from IFSI Orsay-GH Nord Essonne, and ongoing studies in Management and Finances at Management Centre Europe.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com